Treatment of severe refractory pemphigus vulgaris with rituximab

Treatment of severe refractory pemphigus vulgaris with rituximab

Pemphigus vulgaris is a potentially fatal autoimmune bullous disease. High doses of immunosuppressive drugs are used in managing severe cases of pemphigus. Rituximab, an anti-CD20 monoclonal antibody, has proven to be effective in patients with refractory pemphigus vulgaris and pemphigus foliaceus....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Actas dermo-sifiliográficas 2006-01, Vol.97 (1), p.48
Hauptverfasser: Pitarch, Gerard, Sánchez-Carazo, José L, Pardo, José, Torrijos, Arantxa, Roche, Elena, Fortea, José M
Format: Artikel
Sprache:spa
Schlagworte:
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Humans
Immunologic Factors - therapeutic use
Male
Middle Aged
Pemphigus - drug therapy
Remission Induction
Rituximab
Severity of Illness Index
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Pemphigus vulgaris is a potentially fatal autoimmune bullous disease. High doses of immunosuppressive drugs are used in managing severe cases of pemphigus. Rituximab, an anti-CD20 monoclonal antibody, has proven to be effective in patients with refractory pemphigus vulgaris and pemphigus foliaceus. We review cases of pemphigus vulgaris and pemphigus foliaceus not associated with lymphoma that were treated with rituximab, and we report a new case of severe refractory pemphigus vulgaris successfully treated with rituximab.
ISSN:0001-7310
DOI:10.1016/S0001-7310(06)73348-8